is my very quick search understanding Annamycin correct in that this drug is been marketed as a potential better treatment than doxorubicin / low cardio toxicity r/r AML
where as Bisantrene is CPACS, having cardio protection as well as anti cancer synergy and fitting directly into SOC?
If someone can please correct me if I have this the wrong way around, not much time today. Cheers
Cardioprotection thread, page-620
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $273.5M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.61 | $159.4K | 98.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5684 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |